To everyone's surprise, the government has announced its
intention to repeal the famous standard container size regulations
that are set out in the Processed Products Regulations (PPR). These
stipulate mandatory requirements for grades and standards,
including standard container sizes, for canned and frozen fruits
and vegetables that are imported, exported or that are traded
interprovincially. The regulations are voluminous — there
are 73 sections and 12 schedules with dozens of pages of mind
numbing detail. Most consumers don't even know they exist. How
many know, for example, that vegetable soup and pork and beans can
be in 10- and 14-fl oz cans, but it is an offence to use 12-fl oz
cans? Or that ketchup containers must be 375-, 575-, or 750-mL
Changes to the PPR have been a divisive issue for years because
they create winners and losers. For some, the PPR is a small but
helpful protectionist measure; for others, a barrier to the
importation of new or cheaper products. It did provide modest
consumer protection, but the Canadian Food Inspection Agency (CFIA)
wasted resources and wrongly, in my view, even applied it to the
importation of wholesale bulk product to manufacturers who used it
for further processing.
The announcement in the 2012 federal budget was limited to the
repeal of "regulations related to container standards to
enable industry to take advantage of new packaging formats and
technologies, while removing an unnecessary barrier for the
importation of new products from international markets." Other
changes to the PPR will be done as part of the broader legislative
consolidation of CFIA regulations that is coming very soon.
A new CFIA Complaints and Appeals Office
Kudos to Agriculture Minister Ritz and CFIA president George da
Pont for bringing into force an important new administrative
redress mechanism for the CFIA. Readers of this column will know
that I have argued for over a decade that the scope of discretion
and the range of CFIA authorities required a step-wise process to
have regulatory decisions reviewed in an independent and timely
way. If industry is not satisfied with CFIA staff actions in the
enforcement of rules, if there has been undue delay in decisions or
if the regulated party disagrees with decisions made by CFIA
employees related to licensing, registration, permits, orders,
inspection results, seizure, labelling or other regulatory action,
then the CFIA now has a clear process to address the complaint in a
timely way and provide redress if warranted.
After trying to resolve the matter directly with the employee,
the regulated party now has automatic access to a formal written
complaint procedure with a new Complaints and Appeal Office. The
new Office will be guided by the recently released CFIA Statement
of Rights and Service for Producers, Consumers and Other
Stakeholders. Done right, this modest regulatory innovation could
significantly improve the quality of agriculture and food law
enforcement in Canada and could provide a useful precedent for
other areas of regulation.
More changes coming
By the time this is published, we'll have details on
legislative consolidation at the CFIA and, from Health Canada, some
decisions on food-like Natural Health Products. And following the
budget commitment to "streamline and accelerate the process
for how foods are regulated," the introduction of modest
amendments to the Food and Drugs Act to expedite, inter alia, the
process for additive changes.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
The Supreme Court has rendered its decision in Cojocaru v. British Columbia Women's Hospital and Health Centre, a case concerned with the propriety of judicial adoption verbatim of counsel's submissions in the Court's decision.
In an industry where one out of 10,000 drugs makes it to market, and where many drugs fail after millions of dollars of investment, one of the challenges is to create an environment that enhances the chance of success and mitigates the high cost of failures.